Retrospective analysis of safety and efficacy of enhanced recovery pathways in stage II–III colorectal cancer patients submitted to surgery and adjuvant therapy

Table 4 Chemotherapy treatment

Parameters	Cohorts				Comparisons
Parameters	FTLCO	OTLCO	CSLFO	OSLFO
Surgery	Fast-track laparoscopy	Open fast-track	Conventional laparoscopy	Open conventional
Adjuvant chemotherapy	8 cycles of capecitabine and oxaliplatin; every 21 days	8 cycles of capecitabine and oxaliplatin; every 21 days	12 cycles of leucovorin, fluorouracil, and oxaliplatin; every 15 days	12 cycles of leucovorin, fluorouracil, and oxaliplatin; every 15 days
Numbers of patients who received chemotherapy	103	107	113	105	p value
Any grade adverse effects	93 (90)	102 (95)	107 (95)	99 (94)	0.431
Grade 3–4 adverse effects	37 (36)	39 (36)	41 (36)	43 (41)	0.858
Cost (¥/patient)	99,000±10,000	98,500±17,500	102,000±15,000	101,500±10,500	0.151

Categorical and ordinal variables are presented as frequency (percentages) and continuous variables are presented as mean ± standard deviation (SD)
Variables were analyzed by one-way ANOVA
The Tukey test was used for post hoc analysis
A p value less than 0.05 and q value greater than 3.633 were considered significant
The National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 was preferred for evaluation of the chemotherapy-related adverse events
N/A not applicable

ISSN: 1477-7819